Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: steve who wrote (3837)	2/23/2000 11:12:00 AM
From: LiPolymer	Read Replies (2) \| Respond to of 4140

Sorry for the cryptic post. This is something we have been watching for, signs of Lehman selling against their preferred stock. Lehman (and and shorts on their coattails) will not be able to sell it down far enough (and hold it there) to affect the conversion price much. This morning may have been a test, and support quickly developed around $7.50 (fortunately I was at the terminal and got some below that). There could be some negative bias due to the VISX quandary, but SNRS business model does not depend as heavily on per-procedure fees. In the short/mid-term, their revenue will come from sales of their laser systems, but once the market begins to saturate attention may turn to fees. Let's see how much better the LTK patents hold up as compared to VISX. Also, unlike VISX, there are applications for the basic "Sand Method" beyond vision correction. Immediate affects on SNRS will most likely be related to the end of the February Floorless, naked short covering and build-up to the anticipated FDA approval. All IMHO...regards, Gary Smith